Trial record 3 of 3 for: urigen

Previous Study | Return to List | Next Study

Study of U101 for Bladder Pain and/or Urgency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00256542

Recruitment Status : Completed

First Posted : November 21, 2005

Last Update Posted : September 29, 2006

Sponsor:

Information provided by:

Urigen

Study Description

Brief Summary:

The purpose of this study is to determine whether intravesical U101 (alkalinized lidocaine-heparin) treatment reduces the symptoms of pelvic pain and/or urgency of bladder origin.

Condition or disease	Intervention/treatment	Phase
Pelvic Pain Interstitial Cystitis Bladder Diseases	Drug: Alkalinized Lidocaine-Heparin	Phase 2

Study Design


Study Type :	Interventional (Clinical Trial)
Enrollment :	90 participants
Allocation:	Randomized
Intervention Model:	Single Group Assignment
Masking:	Double
Primary Purpose:	Treatment
Official Title:	A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin
Study Start Date :	January 2006
Study Completion Date :	September 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners Pelvic Pain

Drug Information available for: Lidocaine hydrochloride Lidocaine Heparin Heparin sodium

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

Overall improvement in combined symptoms of pain and urgency at 3 weeks

Secondary Outcome Measures :

Safety
Reduction in pain on ten point scale at 3 weeks
Reduction in urgency on ten point scale at 3 weeks
Change in number of voids/24 hours
Change in average void volume
Reduction in PUF score (pelvic pain, urgency/frequency) at 3 weeks
Reduction in O'Leary-Sant score at 3 weeks

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male and female subjects at least 18 years of age.
Subjects must have given written informed consent to participate in this trial.
All female subjects, except those who are post-menopausal and/or surgically sterilized, must consent to use two medically acceptable methods of contraception throughout the entire study period. Medically acceptable methods of contraception that may be used by the subject and/or her partner include: abstinence, birth control pills, diaphragm with spermicide, intrauterine device (IUD), condom and foam, vaginal spermicidal suppository, progestin implant, and Depo-Provera injections.
Subjects must have had symptoms of pelvic pain and/or urgency.
Medical history and physical examination results must be clinically acceptable to the Investigator. Medical Monitor may evaluate subjects who don’t meet eligibility criteria.
Female subjects currently using hormone therapy (HT) must have been using HT for at least 3 months.

Exclusion Criteria:

Subjects less than 18 years of age.
Subjects with known hypersensitivity to heparin or lidocaine.
Female subjects who have a positive pregnancy test at the time of screening, who are pregnant or lactating, or who are planning to become pregnant during the study period.
Subjects who are chronic users of narcotics or who are using any narcotics at the time of study entry.
Subjects who have hepatic disease or clinically significant abnormal liver function tests (more than twice the upper limit of the normal range).
Subjects who do not expect to be available for the entire duration of the study.
Subjects with any coexisting significant medical condition that is likely to interfere with study procedures (cardiovascular, hematological, central nervous system, pulmonary, renal, etc.)
Subjects who have been treated with dimethyl sulfoxide (DMSO) or other bladder instillation therapies within three months prior to study entry.
Subjects who have had cystoscopic dilatation of their bladder or urethra within three months of study entry.
Subjects who have taken or used any investigational drug or device within 30 days before the start of the study, or who are currently enrolled in another investigational study.
Subjects contemplating having or scheduled for any invasive surgical procedures during the study period.
Subjects who are unwilling or unable to abide by the requirements of the study.
History of gastrointestinal (GI) bleeding
Active bleeding from any source
Screening activated partial thromboplastin time (aPTT) above normal limits
Systolic blood pressure (BP) > 180 mmHg or < 90 mmHg at Screening.
Subjects with an actively bleeding lesion/area in the bladder as detected by urinalysis

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00256542

Locations


United States, California
UCSD Medical Center
San Diego, California, United States, 92103
United States, Georgia
Georgia Urology
Cartersville, Georgia, United States, 30120
United States, Illinois
St. Mary's Good Samaritan
Centralia, Illinois, United States, 62801
United States, Kansas
The Urogynecology Center
Overland Park, Kansas, United States, 66215
United States, Michigan
Mid-Michigan Health Centers
Jackson, Michigan, United States, 49201
United States, New York
Central Park Urology
New York City, New York, United States, 10019
United States, North Carolina
The Urology Center
Greensboro, North Carolina, United States, 27403
United States, Oklahoma
Urologic Specialists of Oklahoma, Inc.
Tulsa, Oklahoma, United States, 74146
United States, Pennsylvania
Whitmore Urology Office
Philadelphia, Pennsylvania, United States, 19146

Sponsors and Collaborators

Urigen

Investigators


Principal Investigator:	C. Lowell Parsons, MD	UCSD

More Information

Publications:

Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology. 2005 Jan;65(1):45-8.


ClinicalTrials.gov Identifier:	NCT00256542 History of Changes
Other Study ID Numbers:	URG-101
First Posted:	November 21, 2005 Key Record Dates
Last Update Posted:	September 29, 2006
Last Verified:	August 2006

Keywords provided by Urigen:


interstitial cystitis pelvic pain urgency frequency Pelvic Pain and/or Urgency of Bladder Origin

Additional relevant MeSH terms:


Pelvic Pain Cystitis Cystitis, Interstitial Urinary Bladder Diseases Pain Neurologic Manifestations Signs and Symptoms Urologic Diseases Lidocaine Calcium heparin Heparin Anesthetics, Local Anesthetics	Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Anti-Arrhythmia Agents Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Anticoagulants Fibrinolytic Agents Fibrin Modulating Agents

To Top